How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Level 1 Snow Emergency: Roadways are hazardous with blowing and drifting snow. Roads are also icy; drive carefully. Level 2 Snow Emergency: Roadways are hazardous with blowing and drifting snow. Only ...

There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...

Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. Eric's career includes extensive work in both public and corporate ...

Alexandra Twin has 15+ years of experience as an editor and writer, covering financial news for public and private companies. Marguerita is a Certified Financial Planner (CFP), Chartered Retirement ...

Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...